QQQ   423.41 (-0.57%)
AAPL   167.04 (-0.57%)
MSFT   404.27 (-1.84%)
META   501.80 (+1.54%)
GOOGL   156.01 (+0.35%)
AMZN   179.22 (-1.14%)
TSLA   149.93 (-3.55%)
NVDA   846.71 (+0.76%)
AMD   155.08 (+0.69%)
NIO   4.00 (+2.30%)
BABA   68.88 (+0.09%)
T   16.33 (+1.30%)
F   12.06 (+0.17%)
MU   111.93 (-3.78%)
GE   152.94 (-1.75%)
CGC   7.83 (+20.65%)
DIS   112.43 (-0.45%)
AMC   2.92 (-2.01%)
PFE   25.39 (-0.12%)
PYPL   62.10 (-1.83%)
XOM   118.52 (-0.09%)
QQQ   423.41 (-0.57%)
AAPL   167.04 (-0.57%)
MSFT   404.27 (-1.84%)
META   501.80 (+1.54%)
GOOGL   156.01 (+0.35%)
AMZN   179.22 (-1.14%)
TSLA   149.93 (-3.55%)
NVDA   846.71 (+0.76%)
AMD   155.08 (+0.69%)
NIO   4.00 (+2.30%)
BABA   68.88 (+0.09%)
T   16.33 (+1.30%)
F   12.06 (+0.17%)
MU   111.93 (-3.78%)
GE   152.94 (-1.75%)
CGC   7.83 (+20.65%)
DIS   112.43 (-0.45%)
AMC   2.92 (-2.01%)
PFE   25.39 (-0.12%)
PYPL   62.10 (-1.83%)
XOM   118.52 (-0.09%)
QQQ   423.41 (-0.57%)
AAPL   167.04 (-0.57%)
MSFT   404.27 (-1.84%)
META   501.80 (+1.54%)
GOOGL   156.01 (+0.35%)
AMZN   179.22 (-1.14%)
TSLA   149.93 (-3.55%)
NVDA   846.71 (+0.76%)
AMD   155.08 (+0.69%)
NIO   4.00 (+2.30%)
BABA   68.88 (+0.09%)
T   16.33 (+1.30%)
F   12.06 (+0.17%)
MU   111.93 (-3.78%)
GE   152.94 (-1.75%)
CGC   7.83 (+20.65%)
DIS   112.43 (-0.45%)
AMC   2.92 (-2.01%)
PFE   25.39 (-0.12%)
PYPL   62.10 (-1.83%)
XOM   118.52 (-0.09%)
QQQ   423.41 (-0.57%)
AAPL   167.04 (-0.57%)
MSFT   404.27 (-1.84%)
META   501.80 (+1.54%)
GOOGL   156.01 (+0.35%)
AMZN   179.22 (-1.14%)
TSLA   149.93 (-3.55%)
NVDA   846.71 (+0.76%)
AMD   155.08 (+0.69%)
NIO   4.00 (+2.30%)
BABA   68.88 (+0.09%)
T   16.33 (+1.30%)
F   12.06 (+0.17%)
MU   111.93 (-3.78%)
GE   152.94 (-1.75%)
CGC   7.83 (+20.65%)
DIS   112.43 (-0.45%)
AMC   2.92 (-2.01%)
PFE   25.39 (-0.12%)
PYPL   62.10 (-1.83%)
XOM   118.52 (-0.09%)
Free Trial
NASDAQ:SGYP

Synergy Pharmaceuticals (SGYP) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)
Free SGYP Stock Alerts
Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
N/A
50-Day Range
$0.01
▼
$0.03
52-Week Range
N/A
Volume
N/A
Average Volume
6.08 million shs
Market Capitalization
$7.44 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock Analysis
Stock Analysis
SGYP stock logo

About Synergy Pharmaceuticals Stock (NASDAQ:SGYP)

Synergy Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat gastrointestinal diseases and disorders. Its lead product is plecanatide, a novel uroguanylin based gastrointestinal platform that is traded under the TRULANCE name for the treatment of chronic idiopathic constipation and irritable bowel syndrome. The company also develops dolcanatide to treat mild-to-moderate ulcerative colitis. It has a licensing agreement with Cipher Pharmaceuticals Inc. to develop, market, distribute, and sell TRULANCE in Canada. Synergy Pharmaceuticals Inc. is headquartered in New York, New York. On December 12, 2018, Synergy Pharmaceuticals Inc. along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.

SGYP Stock News Headlines

April 12, 2024 | seekingalpha.com
Jose Solorio
January 2, 2024 | msn.com
PYC Therapeutics and Google Cloud partner for new precision medicines
April 18, 2024 | InvestorPlace (Ad)
The Next Nvidia?
The Next Nvidia? Wall Street legend has just uncovered one tiny Maryland company that could become the next Nvidia. Few in the media are talking about this story yet… but in the next 6 months that’s all they’ll talk about.
May 9, 2023 | investing.com
Synergy Pharmaceuticals Inc Unit (SGYPU)
April 12, 2023 | forbes.com
Market Factor Synergy Signals Exciting Growth For Digital Pathology
March 29, 2023 | bbc.co.uk
Different resistors
March 28, 2023 | bbc.co.uk
Mains cables
March 28, 2023 | bbc.co.uk
Energy changes in braking
April 18, 2024 | InvestorPlace (Ad)
The Next Nvidia?
The Next Nvidia? Wall Street legend has just uncovered one tiny Maryland company that could become the next Nvidia. Few in the media are talking about this story yet… but in the next 6 months that’s all they’ll talk about.
December 18, 2022 | thestreet.com
Synergy Pharmaceuticals (SGYP) Stock Higher in After-Hours Trading Following Paulson Investment
September 13, 2022 | investing.com
Jiangxi Synergy Pharmaceutical Co Ltd (300636)
May 16, 2022 | seekingalpha.com
Syros Pharmaceuticals, Inc. (SYRS) CEO Nancy Simonian on Q1 2022 Results - Earnings Call Transcript
January 18, 2022 | thestreet.com
Here's a Reason Why Synergy Pharma (SGYP) Stock Is Rallying Today
December 2, 2021 | finanznachrichten.de
OKYO Pharma LTD: OKYO Pharma Limited: Directorate Change
See More Headlines
Receive SGYP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Synergy Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/08/2018
Today
4/18/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:SGYP
CUSIP
87163930
CIK
1347613
Web
www.synergypharma.com
Phone
212-297-0020
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($1.02)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-224,330,000.00
Net Margins
-332.11%
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
-118.14%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.52
Quick Ratio
0.38

Sales & Book Value

Annual Sales
$16.82 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.02) per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
248,040,000
Free Float
N/A
Market Cap
$7.44 million
Optionable
Optionable
Beta
4.94
10 Best Cheap Stocks to Buy Now Cover
10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Troy Hamilton Pharm.D. (Age 47)
    CEO & Director
  • Mr. Gary G. Gemignani (Age 54)
    Exec. VP & CFO
  • Gem Gokmen Hopkins
    VP of Investor Relations and Corp. Communications
  • Ms. Pamela Cebulski
    Sr. VP of Marketing
  • Ms. Marianne Jackson
    Sr. VP of Sales & Market Access

Key Competitors

View All Competitors

SGYP Stock Analysis - Frequently Asked Questions

How were Synergy Pharmaceuticals' earnings last quarter?

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) issued its earnings results on Thursday, November, 8th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.13) by $0.01. The biopharmaceutical company had revenue of $11.11 million for the quarter, compared to the consensus estimate of $15.65 million.

What other stocks do shareholders of Synergy Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Synergy Pharmaceuticals investors own include Novavax (NVAX), Immunomedics (IMMU), Progenics Pharmaceuticals (PGNX), Inovio Pharmaceuticals (INO), ACADIA Pharmaceuticals (ACAD), Cara Therapeutics (CARA), OPKO Health (OPK), Gilead Sciences (GILD), Exelixis (EXEL) and

This page (NASDAQ:SGYP) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners
[Urgent!] Generational Wealth Gameplan
Crypto 101 Media
Biden’s $374B Giveaway Into This Sector
DTI
Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS
Paradigm Press
He Is Giving Away Bitcoin
Crypto Swap Profits
The Next Nvidia?
InvestorPlace
How Biden has already won 2024
Porter & Company
Options trading has suddenly become more reliable.
Eagle Publishing
Top 5 AI Stocks to Buy for 2024
Market Moving Trends